The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates

Alzheimer's and Dementia

Volumn 10, Issue 3, 2014, Pages 271-283

  Davtyan, Hayk ^a,b   Ghochikyan, Anahit ^a   Petrushina, Irina ^b   Hovakimyan, Armine ^a   Davtyan, Arpine ^a   Cribbs, David H ^b   Agadjanyan, Michael G ^a,b  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AD epitope vaccine; Alzheimer's disease (AD); Electroporation; Mapping of B and T cell immune responses; Rhesus macaques

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA; AMYLOID BETA ANTIBODY; ANTIBODY; ASPARAGYLTYROSYLSERYLLEUCYLASPARTYLLYSYLISOLEUCYLISOLEUCYLVALYLASPARTYLTYROSYLASPARAGINYLLEUCYLGLUTAMINYLSERYLLYSYLISOLEUCYLTHREONYLLEUCYLPROLINE; AV 1955; AV 1959; EPITOPE; LEUCYLGLUTAMYLTYROSYLISOLEUCYLPROLYLGLUTAMYLISOLEUCYLTHREONYLLEUCYLPROLYLVALYLISOLEUCYLALANYLALANYLLEUCYLSERYLISOLEUCYLALANYLGLUTAMYLSERINE; LEUCYLISOLEUCYLASPARAGINYLSERYLTHREONYLLYSYLISOLEUCYLTYROSYLSERYLTYROSYLPHENYLALANYLSERYLVALYLISOLEUCYLSERYLLYSYLVALYLASPARAGINYLGLUTAMINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; TETANUS TOXIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; DNA VACCINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FEMALE; GENETIC POLYMORPHISM; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTIBODY PRODUCTION; C57BL MOUSE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MALE; MICE, INBRED C57BL; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, DNA;

EID: 84899637729     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.12.003     Document Type: Article

References (53)

1. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-6.
3. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-12.
4. Klyubin I,Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005; 11:556-61.
5. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 2012;73:504-17.
6. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004;16:599-606.
7. Orgogozo JM, Gilman S, Dartigues JM, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54.
8. Schenk D. Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002;3:824-8.
9. Lobello K, Ryan JM, Liu E, Rippon G, Black R. Targeting beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. Int J Alzheimers Dis 2012;2012:628070.
10. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62.
11. Holmes C, Boche D,Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23.
12. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 2006;65:1040-8.
13. Patton RL, Kalback WM, Esh CL, Kokjohn TA, van Vickle GD, Luehrs DC, et al. Amyloid-beta peptide remnants in AN-1792- immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006;169:1048-63.
14. Weiskopf D,Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009;22:1041-50.
15. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-5.
16. Eli Lilly and Company announces top-line results on Solanezumab Phase 3 clinical trials in patients with Alzheimer's disease, 2012. Available at: http://newsroom.lilly.com/releasedetail.cfm?releaseid5 702211.
17. Johnson & Johnson announces discontinuation of Phase 3 development of Bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease, 2012. Available at: http://www.jnj.com/connect/ news/all/johnson-and-johnson- announces-discontinuation-of-phase-3- development-of-bapineuzumab-intravenous- iv-in-mild-to-moderatealzheimers- disease.
18. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from betaamyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005;174:1580-6.
19. Ghochikyan A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets 2009;8:128-43.
20. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Ab species in amyloid precursor protein transgenic mice. J Neurosci 2007;27:12721-31.
21. Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci 2013;33:4923-34.
22. Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, et al. MER5101, a novel Abeta1-15:DT conjugate vaccine, generates a robust anti-Abeta antibody response and attenuates Abeta pathology and cognitive deficits in APPswe/PS1DeltaE9 transgenic mice. J Neurosci 2013; 33:7027-37.
23. Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011;31:9323-31.
24. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLoS One 2008;3:e21-4.
25. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012;11:597-604.
26. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med 2010;220:95-106.
27. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6:108-19.
28. Delrieu J, Ousset PJ, Caillaud C, Vellas B. 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 2012; 120(Suppl 1):186-93.
29. Ghochikyan A, Vasilevko V, Petrushina I, Tran M, Sadzikava N, Babikyan D, et al. Generation and characterization of the humoral immune response to DNA immunization with a chimeric b-amyloidinterleukin- 4 minigene. Eur J Immunol 2003;33:3232-41.
30. Evans CF, Davtyan H, Petrushina I, Hovakimyan A, Davtyan A, HannamanD, et al.Epitope-basedDNAvaccine forAlzheimer's disease: translational study in macaques. Alzheimers Dement 2013 (in press).
31. Ghochikyan A, Davtyan H, Petrushina I, Hovakimyan A, Movsesyan N, Davtyan A, et al. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccine Immunother 2013;9:1002-10.
32. Davtyan H, Ghochikyan A, Movsesyan N, Ellefsen B, Petrushina I, Cribbs DH, et al. Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses. Neurodegener Dis 2012;10:261-4.
33. Cribbs DH, Ghochikyan A, Tran M, Vasilevko V, Petrushina I, Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003; 15:505-14.
34. Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M. Characterization of murine immunoglobulin G antibodies against human amyloid- b 1-42. Neurosci Lett 2001;307:101-4.
35. Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, et al. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide. DNA Cell Biol 2001;20:723-9.
36. Lemere CA, Maron R, Selkoe DJ, Weiner HL. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 2001;20:705-11.
37. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 2005;58:430-5.
38. James EA, Bui J, Berger D, Huston L, Roti M, Kwok WW. Tetramerguided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD41 T cells and suggests HLA-based differences in epitope recognition. Int Immunol 2007;19:1291-301.
39. de Groot N, Doxiadis GG, De Groot NG, Otting N, Heijmans C, Rouweler AJ, et al. Genetic makeup of the DR region in rhesus macaques: gene content, transcripts, and pseudogenes. J Immunol 2004;172:6152-7.
40. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1:751-61.
41. Zhou J, Fonseca MI, Kayed R, Hernandez I, Webster SD, Yazan O, et al. Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation 2005;2:28.
42. Qu B, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 2004;61:1859-64.
43. Qu BX, Xiang Q, Li L, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci 2007;260:204-13.
44. Tokita Y, Kaji K, Lu J, Okura Y, Kohyama K, Matsumoto Y. Assessment of non-viral amyloid-beta DNAvaccines on amyloid-beta reduction and safety in rhesus monkeys. J Alzheimers Dis 2010;22:1351-61.
45. Zahn LM, Jasny BR, Culotta E, Pennisi E. A barrel of monkey genes. Science 2007;316:215.
46. ImbertG,Marrony S, Ulrich P,GoldsmithP.Antibodyimmune response in cynomolgus monkeys following treatment with the active Ab immunotherapy CAD106. Alzheimers Dement 2009;5(Suppl):P427.
47. Del Giudice G. New carriers and adjuvants in the development of vaccines. Curr Opin Immunol 1992;4:454-9.
48. Derhovanessian E, Solana R, Larbi A, Pawelec G. Immunity, ageing and cancer. Immun Ageing 2008;5:11.
49. Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 2009;8:144-59.
50. Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011;68:1526-35.
51. Sperling R, Salloway S, Raskind MA, Ferris S, Liu E, Yuen E, et al. A randomized double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ?4 carriers. In: 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden, 2012.
52. Salloway S, Sperling R, Honig L, Porsteinsson A, Sabbagh M, Liu E, et al. A randomized double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ?4 non-carriers. In: 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden, 2012.
53. Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, Movsesyan N, et al. Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J Biol Chem 2007;282:22376-86.